Notice on Convening the 2024 Annual General Meeting
Filed with SSE · · 10 pages · Chinese
Bio-Thera Solutions, Ltd. on 6ix
Earlier from Bio-Thera Solutions
- Announcement on the Latest Development of BAT1806 (Tocilizumab) Business
- Announcement on Voluntary Disclosure of Progress of Down-payment Received for Signing Authorization License and Commercialization Agreement with Intas Pharmaceuticals Ltd. for BAT2506 (Golimumab) Injection
- Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
- Announcement on Resolution of the 18th Meeting of the 2nd Board of Supervisors
- Announcement on Obtaining Acceptance of Application for Marketing Authorization of Golimumab Injection (BAT2506)
Later from Bio-Thera Solutions
- Bio-Thera Solutions Presents Clinical Data for multiple products at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- Announcement on Election of Employee Representative Director for the Third Board of Directors
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT7111 for Injection
- Announcement on Share Reduction Plan for Shareholders
- Report for Q1 2025
Follow Bio-Thera Solutions into a list and get an email when it puts out news.
Follow Bio-Thera Solutions